Eur Rev Med Pharmacol Sci 2018; 22 (14): 4488-4492
DOI: 10.26355/eurrev_201807_15502

Expressions and effects of G250, Bax and Bcl-2 in rats with renal clear cell carcinoma

Y.-Q. Wang, C. Liu, Z.-F. Shan, Q.-Z. Liu, Y.-S. Cui, L.-Q. Yang

Department of Urology, the Affiliated Yantai Hospital of Qingdao University Medical College, Yantai, P.R. China. jzhang76@sina.com


OBJECTIVE: To investigate the expressions and effects of G250, B-cell lymphoma-2 associated X protein (Bax) and Bcl-2 in rats with renal clear cell carcinoma (RCCC).

MATERIALS AND METHODS: A total of 66 male Sprague-Dawley (SD) rats were selected, among which 56 were selected to establish RCCC rat model and the remaining 10 were selected as control group. Three weeks after modeling, 4 rats failed in the modeling. Expressions of G250 in RCCC rat model group and healthy rat model control group were detected by Reverse Transcription-Polymerase Chain Reaction (RT-PCR); expressions of Bcl-2 and Bax in each group were detected by Western blot and their effects were analyzed.

RESULTS: The positive expression rates of G250 in 52 RCCC rats in model group and 10 healthy rats in control group were 83.3% and 0%, respectively. The results showed that expression of G250 had a certain correlation with the pathological changes of RCCC (p < 0.01). Expressions of Bax and Bcl-2 were up-regulated in the RCCC group, while expressions were down-regulated in the healthy control group (p < 0.05).

CONCLUSIONS: G250, as a new specific marker of renal cell carcinoma, is involved in the pathological changes of renal cell carcinoma. Joint detection of Bax and Bcl-2 can be used as an important index for the diagnosis of RCCC.

Free PDF Download

To cite this article

Y.-Q. Wang, C. Liu, Z.-F. Shan, Q.-Z. Liu, Y.-S. Cui, L.-Q. Yang
Expressions and effects of G250, Bax and Bcl-2 in rats with renal clear cell carcinoma

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 14
Pages: 4488-4492
DOI: 10.26355/eurrev_201807_15502